Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

Commission File Number 000-54949

BioAdaptives Inc.

(Exact name of registrant as specified in its charter)

Delaware		46-2592228
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

2620 Regatta Drive, Suite 102, Las Vegas, NV		89128
(Address of principal executive offices)		(Zip Code)

(702) 659-8829

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-Accelerated filer	☐	Smaller reporting Company	☒
Emerging Growth Company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES ☒ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

776,464,023 common shares issued and outstanding as of November 8, 2023

Form 10-Q

Table of Contents

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of operations		16
Item 3. Quantitative and Qualitative Disclosures about Market Risk		23
Item 4. Controls and Procedures		23

PART II – OTHER INFORMATION
Item 1. Legal Proceedings		25
Item 1A. Risk Factors		25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		26
Item 3. Defaults Upon Senior Securities		27
Item 4. Mine Safety Disclosure		27
Item 5. Other Information		27
Item 6. Exhibits		27
Signatures		28

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30,			December 31,
	2023			2022

ASSETS
Current Assets:
Cash	$	152,072		$	25,405
Accounts receivable		3,344			-
Marketable securities		11			42
Inventory		7,250			8,877
Total Current Assets		162,677			34,324

License and patent, net		166,625			2,990
TOTAL ASSETS	$	329,302		$	37,314

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities		433,375			409,920
Derivative liabilities		708,584			686,856
Current portion of convertible notes - net of discount of $79,829 and $7,647		325,671			381,793
Note payable - related party		7,520			10,246
Total Current Liabilities		1,475,150			1,488,815

Total Liabilities		1,475,150			1,488,815

Stockholders' Deficit:
Preferred stock, ($0.0001 par value, 10,000,000 shares authorized;
Series A Preferred Stock 4,000,000 shares designated; 2,850,000 and 1,600,000 issued and outstanding, respectively		285			160
Series B Preferred Stock 6,000,000 shares designated; 2,250,000 and 0 share issued and outstanding, respectively		225			-
Common stock ($0.0001 par value, 1,250,000,000 shares authorized; 776,474,023 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)		77,647			25,255
Additional paid-in capital		6,771,839			6,074,763
Accumulated deficit		(7,995,844	)		(7,551,679	)
Total Stockholders' Deficit		(1,145,848	)		(1,451,501	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	329,302		$	37,314

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

	Three Months Ended						Nine months ended
	September 30,						September 30,
	2023			2022			2023			2022

Revenues	$	15,649		$	3,337		$	21,364		$	13,192
Cost of revenue		10,999			1,337			13,244			7,096
Gross Profit		4,650			2,000			8,120			6,096

Operating Expenses
General and administrative		33,706			43,981			60,258			236,698
Professional fees		25,514			30,588			76,010			102,532
Amortization of license and patent		37,643			4,476			38,989			61,464
Total Operating Expenses		96,863			79,045			175,257			400,694

Other Income (Expense)
Unrealized gain (loss) on marketable securities		(11	)		(31	)		(31	)		(158	)
Interest expense		(20,625	)		(94,106	)		(123,941	)		(199,572	)
Change in fair value of derivative liabilities		261,488			(105,143	)		8,644			(272,965	)
Loss on settlement of debt		(161,700	)		-			(161,700	)		-
Total Other Income (Expense)		79,152			(199,280	)		(277,028	)		(472,695	)

Loss before income taxes		(13,061	)		(276,325	)		(444,165	)		(867,293	)

Net Loss	$	(13,061	)	$	(276,325	)	$	(444,165	)	$	(867,293	)

Net Loss Per Common Share:
Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)

Weighted Average Number of Common Shares Outstanding:
Basic and Diluted		730,006,523			89,333,996			482,799,498			77,615,330

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

For the Three and Nine months ended September 30, 2022

	Series A Preferred stock				Series B Preferred stock				Common stock				Additional paid-in		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		capital		Deficit			Total

Balance, December 31, 2022		1,600,000	$	160		-	$	-		252,554,765	$	25,255	$	6,074,763	$	(7,551,679	)	$	(1,451,501	)

Common stock issued for conversion of debt		-		-		-		-		132,382,517		13,239		94,797		-			108,036
Net loss for the period		-		-		-		-		-		-		-		(287,187	)		(287,187	)
Balance, March 31, 2023		1,600,000	$	160		-	$	-		384,937,282	$	38,494	$	6,169,560	$	(7,838,866	)	$	(1,630,652	)

Common stock issued for conversion of debt		-		-		-		-		191,536,741		19,153		76,904		-			96,057
Net loss for the period		-		-		-		-		-		-		-		(143,917	)		(143,917	)
Balance, June 30, 2023		1,600,000	$	160		-	$	-		576,474,023	$	57,647	$	6,246,464	$	(7,982,783	)	$	(1,678,512	)

Series A preferred stock issued for license fee		1,250,000		125		-		-		-		-		22,500		-			22,625
Series B preferred stock issued for settlement of debt - related party		-		-		750,000		75		-		-		164,925		-			165,000
Series B preferred stock issued for license fee		-		-		1,500,000		150		-		-		179,850		-			180,000
Common stock issued for cash		-		-		-		-		200,000,000		20,000		158,100		-			178,100
Net loss for the period		-		-		-		-		-		-		-		(13,061	)		(13,061	)
Balance, September 30, 2023		2,850,000	$	285		2,250,000	$	225		776,474,023	$	77,647	$	6,771,839	$	(7,995,844	)	$	(1,145,848

Table of Contents

For the Three and Nine months ended September 30, 2023

	Series A
	Preferred				Common				Additional
	stock				stock				paid-in		Accumulated
	Shares		Amount		Shares		Amount		capital		Deficit			Total

Balance, December 31, 2021		1,600,000	$	160		50,819,780	$	5,082	$	5,557,828	$	(6,656,109	)	$	(1,093,039	)

Common stock issued for conversion of debt		-		-		7,540,799		754		51,263		-			52,017
Debts forgiveness - related party		-		-		-		-		10,000		-			10,000
Net loss for the period		-		-		-		-		-		(367,131	)		(367,131	)
Balance, March 31, 2022		1,600,000	$	160		58,360,579	$	5,836	$	5,619,091	$	(7,023,240	)	$	(1,398,153	)

Common stock issued for conversion of debt		-		-		19,096,904		1,910		119,705		-			121,615
Warrant issued for Patent’s acquisition		-		-		-		-		5,429		-			5,429
Net loss for the period		-		-		-		-		-		(223,837	)		(223,837	)
Balance, June 30, 2022		1,600,000	$	160		77,457,483	$	7,746	$	5,744,225	$	(7,247,077	)	$	(1,494,946	)

Common stock issued for conversion of debt		-		-		55,478,381		5,548		169,865		-			175,413
Net loss for the period		-		-		-		-		-		(276,325	)		(276,325	)
Balance, September 30, 2022		1,600,000	$	160		132,935,864	$	13,294	$	5,914,090	$	(7,523,402	)	$	(1,595,858	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

(UNAUDITED)

	Nine months ended
	September 30,
	2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(444,165	)	$	(867,293	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities		(8,644	)		272,965
Amortization of license and patent		38,989			61,464
Amortization of debt discount		92,318			161,221
Loss on settlement of debt		161,700			-
Unrealized loss on investments in marketable securities		31			158
Changes in operating assets and liabilities:
Accounts receivable		(3,344	)		-
Inventory		1,627			(3,250	)
Prepaid expense and other current assets		-			1,000
Accounts payable and accrued liabilities		29,481			172,177
Due to related party		(470	)		1,803
Net Cash Used in Operating Activities		(132,477	)		(199,755	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance for common stock		178,100			1,623
Proceed from related party		51,044			1,623
Repayment to related party		(50,000	)		(1,623	)
Repayment of notes payable - related party		-			(25,272	)
Proceeds from convertible notes		80,000			160,000
Net Cash Provided by Financing Activities		259,144			136,351

Net change in cash		126,667			(63,404	)
Cash at beginning of period		25,405			82,936
Cash at end of period	$	152,072		$	19,532

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	4,728

NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	$	150,000		$	142,000
Issuance of common stock for conversion of debt	$	204,093		$	349,045
Issuance Series A preferred stock for license fee	$	22,625		$	-
Issuance Series B preferred stock for license fee	$	180,000		$	-
Issuance Series B preferred stock for settlement of debt - related party	$	165,000		$	-
Debts forgiveness - related party	$	-		$	10,000
Warrant issued for Patent's acquisition	$	-		$	5,429

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

BioAdaptives, Inc. (“BioAdaptives” or the “Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. The Company acquired assets relating to the investigation, development and marketing of nutraceutical products; equipment designed to improve the bioavailability of nutrients in humans and animals; and licenses for specific products.

We commenced investigation of the role of various botanicals in primitive cell development and proliferation, including certain algae along with herbs used in Traditional Chinese Medicine and Ayurvedic Practice. In the course of this investigation, BioAdaptives identified several potential human and animal products. The Company terminated further work on the equipment and products licensed in its early stages to concentrate on these products, for both human and animals.

The Company’s current nutraceutical products are natural plant- and algal-based dietary supplements for humans and animals developed with our knowledge of natural foods. Our product lines include PluriCell®, PluriPain®, and PrimiLung™ for humans along with Equine All-in-One™ and a related Booster for horses.

Our human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance and we have developed products to utilize these advances.

The Company also markets the Lung Cleanser™ medical device, which is sold with our PrimiLung® product as part of a Lung Armor™ package. Additionally, during a prior reporting period, the Company acquired patent rights to a method to embed oxygen in water and is developing commercial products based on this technology that will augment and complement our current product lines.

All of these products are sold under licensing and manufacturing agreements with third parties and our current activities are reliant on marketing and distributing products developed and owned by others.

In February 2022, the Company acquired US Patent rights to a process that increases dissolved oxygen in water. The process produces MorO2, ingestion of which is believed to increase diffusion of oxygen into muscle tissues. The Company is continuing to evaluate a business plan to manufacture and market products based on the MorO2 technology.

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on March 31, 2023, have been omitted.

Table of Contents

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Earnings (loss) per share

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued.

Financial Instruments and Fair Value Measurements

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level as of September 30, 2023, and December 31, 2022, measured at fair value on a recurring basis:

	Total Carrying Value as of September 30,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	11	$	11	$	-	$	-

Liabilities
Derivative liabilities	$	708,584	$	-	$	-	$	708,584

Table of Contents

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $7,995,844 as of September 30, 2023. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company’s contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities aa of September 30, 2023, and December 31, 2022, consists of the following:

	September 30,		December 31,
	2023		2022
Accounts payable	$	4,792	$	6,939
Accrued salary		300,000		300,000
Accrued interest		127,564		101,966
Accrued liabilities		1,019		1,015
	$	433,375	$	409,920

Table of Contents

5. CONVERTIBLE NOTES

Convertible notes as of September 30, 2023, and December 31, 2022, consist of the following:

	September 30,			December 31,
	2023			2022
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		94,500			-
Total convertible notes payable		405,500			389,440

Less: Unamortized debt discount		(79,829	)		(7,647	)
Total convertible notes		325,671			381,793

Less: current portion of convertible notes		325,671			381,793
Long-term convertible notes	$	-		$	-

For the nine months ended September 30, 2023, and 2022, the interest expense on convertible notes was $31,401 and $37,903, respectively. As of September 30, 2023, and December 31, 2022, the accrued interest was $126,294 and $100,919, respectively.

The Company recognized amortization expense related to the debt discount of $92,318 and $161,221 for the nine months ended September 30, 2023, and 2022, respectively, which is included in interest expense in the statements of operation.

Conversion

During the nine months ended September 30, 2023, the Company converted notes with principal amounts of $78,440 and accrued interest of $6,026 into 323,919,258 shares of common stock. The corresponding derivative liability at the date of conversion of $64,258 was credited to additional paid in capital.

Convertible Notes – Issued during the year ended December 31, 2018

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of these convertible notes are summarized as follows:

	·	Term two years;

	·	Annual interest rates 12%;

	·	Convertible at the option of the holders at any time

	·	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes - Issued during the year ended December 31, 2021

During the year ended December 31, 2021, the Company issued a total principal amount of $222,500 in convertible note for cash proceeds of $205,000. The terms of convertible note are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

During the year ended December 31, 2021, the Company converted principal of $172,050 and accrued interest of $6,200 into 17,787,355 shares of common stock.

Table of Contents

Convertible Notes - Issued during the year ended December 31, 2022

During the year ended December 31, 2022, the Company issued a total principal amount of $211,500 in convertible notes for cash proceeds of $195,000. The terms of convertible notes are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Convertible Notes - Issued during the year ended December 31, 2023

During the nine months ended September 30, 2023, the Company issued a total principal amount of $94,500 in convertible notes for cash proceeds of $80,000. The terms of convertible notes are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at any time

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the nine months ended September 30, 2023, amounted to $728,213, and $150,000 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $578,213 was recognized as a “day 1” derivative loss.

6. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

Table of Contents

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of September 30, 2023. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

For the nine months ended September 30, 2023, and the year ended December 31, 2022, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Nine months ended			Year ended
	September 30,			December 31,
	2023			2022
Expected term	0.18- 1.00 years			0.06 - 0.51 years
Expected average volatility	141% - 288		%	72% - 164		%
Expected dividend yield		-			-
Risk-free interest rate	4.76% - 5.53		%	0.17% - 4.72		%

The following table summarizes the changes in the derivative liabilities during the nine months ended September 30, 2023.

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		150,000
Addition of new derivatives recognized as loss on derivatives		578,213
Settled on issuance of common stock		(119,628	)
Gain on change in fair value of the derivative		(586,857	)
Balance - September 30, 2023	$	708,584

The aggregate (gain) loss on derivatives during the nine months ended September 30, 2023, and 2022 was as follows.

	Nine months ended
	September 30,
	2023			2022
Day one loss due to derivative liabilities on convertible notes	$	578,213		$	44,933
(Gain) loss on change in fair value of the derivative liabilities		(586,857	)		228,032
	$	(8,644	)	$	272,965

Table of Contents

7. STOCKHOLDERS’ EQUITY

Preferred Stock

On January 24, 2022, the Board of Directors of the Company’s, approved for an increase in the number of authorized shares of the Company’s preferred stock from 5,000,000 shares to 10,000,000 shares.

The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which 4,000,000 have been designated as Series A Preferred Stock and 6,000,000 have been designated as Series B Preferred Stock.

Series A Preferred Stock

On February 6, 2020, the Company established its Series A Preferred Stock, par value $0.001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.

The Company may use the Series A Preferred Stock for the purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio.

During the nine months ended September 30, 2023, the Company issued 1,250,000 shares of Series A Preferred Stock valued at $22,625 for license fee.

There are 2,850,000 and 1,600,000 shares of Series A shares issued as of the date of this filing as of September 30, 2023, and December 31, 2022, respectively.

Series B Preferred Stock

On January 24, 2022, the Company established its Series B Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 6,000,000 shares of Series B Preferred Stock.

The Company may use the Series B Preferred Stock for the purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series B Preferred Stock have enhanced voting privileges (100:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio.

During the nine months ended September 30, 2023, the Company issued 1,500,000 shares of Series B Preferred Stock valued at $180,000 for license fee.

During the nine months ended September 30, 2023, the Company issued 750,000 shares of Series B Preferred Stock valued at $165,000 for settlement of debt of $3,300. As a result, the Company recorded loss on settlement of debt of $161,700.

As of September 30, 2023, and December 31, 2022 2,250,000 and 0 shares of Series B Preferred Stock are issued and outstanding, respectively.

Common Stock

On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2023.

As of September 30, 2023, and December 31, 2022, there were 776,474,023 and 252,544,765 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of September 30, 2023, and December 31, 2022, there were 10,000 shares of the Company’s common stock issuable.

Fiscal year 2023

During the nine months ended September 30, 2023, the Company issued Common shares as follows;

	·	323,919,258 shares of common stock valued at $204,093 for conversion of debt.
	·	200,000,000 shares of common stock at $0.001 per share, net of offering cost of $21,900.

Table of Contents

Warrant

On February 6, 2022, in conjunction with purchase of patent, the Company granted 1,000,000 shares for period of two years with exercise price of $0.006 per share. The fair value of granted shares at the issuance date was $5,429. The Company recorded warrant as additional paid-in-capital.

The estimated fair values of the warrant are as follows:

	Year Ended
	December 31,
	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

8. RELATED PARTY TRANSACTIONS

Notes payable – related party.

During the nine months ended September 30, 2023, and 2022, the Company repaid notes payable to a related party and accrued interest of $3,300 and $30,000 and recognized interest of $54 and $448, respectively.

As of September 30, 2023, and December 31, 2022, the Company recorded notes payable - related party of $5,144 and $8,444 and accrued interest of $1,268 and $1,047, respectively. The note is a 4% interest bearing promissory note that the term is 1 year.

Due to related party

During the nine months ended September 30, 2023, Dr. Edward E. Jacobs, M.D., our CEO, advanced $51,044 for operating expenses and the Company repaid $50,470. As of September 30, 2023, and December 31, 2022, the Company recorded due to related party of $2,377 and $1,802, respectively.

License and patent

As of September 30, 2023, and December 31, 2022, License and patent consist of the following:

	September 30,			December 31,
	2023			2022
License	$	182,000		$	-
Patent		5,429			5,429
		187,429			5,429
Accumulated amortization		(20,804	)		(2,439	)
	$	166,625		$	2,990

The term of licenses is a range from 1 to 3 years for the certain products. The Company agrees to pay a royalty on sales of the Products during the term of licensees equivalent to 2 – 5% of gross product sales amounts (“GPSA”). Such royalty shall be payable only after the Licensor attains a GPSA of $20,000 to $30,000 in any calendar month, and shall be payable on the entire GPSA for such period.

For the nine months ended September 30, 2023, the Company recorded amortization expense of $38,989.

9. SUBSEQUENT EVENTS

On October 11 2023, the Company filed a new Reg A for the marketing of 250,000,000 common shares at a price range of $0.001 to $0.003, to be determined after qualifying. This new Reg A is to provide additional funding for the marketing for BioAdaptives itself, and also for its wholly owned subsidiary, LiveStock Impact Inc, The Company is looking to expand its range of targeted human health supplements. It is also focused on the marketing effort of LiveStock Impact, Inc and its wholesale activities as well as its interest in botanical drugs. Towards this end, since October, the Company has been working with a professional entity on its press releases and marketing promotions. It expects to intensify its marketing outreach in the next two quarters. The Company also announced its launching of a new Lung Health supplement, Lung Fortress, a robust all natural supplement designed to foster Pulmonary Health.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This current report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock. As used in this quarterly report, the terms “we”, “us”, “our”, “Company” and "BioAdaptives" mean BioAdaptives Inc., unless otherwise indicated.

Table of Contents

1.OUR BUSINESS

Overview

BioAdaptives’ core business is to investigate, market and distribute natural plant, algal and mushroom-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties.

Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared medical device, the Lung Flute™, which the Company called Lung Cleanser™. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual property relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.

The Company’s current products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness™. Cell Rejuven™ is an anti-aging cell rejuvenation formulation; ProteinNMore™ is a unique turbo charged balanced premium protein blend of natural ingredients that optimizes bioavailability of nutrients to rapidly build lean bulk and maximize contractile strength of muscles. We also market the Lung Cleanser™ and PrimiLungs™ product in our Lung Armor™ packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the non-invasive FDA-cleared device. MindNMemory™ is a nootropic formulation designed to enhance mental clarity and memory; SleepEZ™ is a natural soporific that aids relaxation and sleep quality. We acquired the SleepEZ™ license in 2021 as PrimiSleep™, and the revised formulation for MindnMemory™ during 2022, and have commenced marketing activities for these products. Sales of the Lung Cleanser™ have not met our expectations and we anticipate concentrating in marketing this device through wholesale channels and on Amazon instead.

Our animal products include an Equine All-in-One™ and Equine All-In-One Plus™ formulation, which we market to trainers, horse owners and boarding stables, and a Canine All-in-One™ that we market directly to consumers. Anecdotal and testimonial reports are that the equine products provide significant relief from exercise induced pulmonary hemorrhaging, as well as improved coat and mane appearance and hoof health. The canine products have demonstrated significant rejuvenating benefits for older dogs, improving overall appearance and energy levels. Effective April 2023, FBRTherapy Division has been appointed its exclusive Distributor for all LiveStock Impact’s products, as such The Company also negotiated with the supplier for the exclusive marketing rights to these products from the non-exclusive license it has held since June 2022. In this first quarter of the exclusive wholesale agreement, its wholesale volume has surpassed the past 9 months total by 400%. Granted due to the switch from retail to wholesale the margins are much tighter, but we believe in 2024, the expanded sales will greatly benefit this wholly owned subsidiary and justifies its eventual independence.

Effective February 2, 2022, the Company acquired the option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. Effect June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of this Product. However, since technical and operational problems prevented completion of the planned pilot run, and as a result we are still working to find a solution these issues and explore how to deploy the technology.

Since the latter part of March, the Company has started to explore the Botanical Drugs sphere. We acquired the non exclusive licenses from Dr. Yaguang Liu, LY Research for Glucose Management, Eye Health due to Myopia and Presbyopia and a resveratrol product. Dr Liu has had over 40 years of research and development in the Botanical Drugs area. We are exploring the opportunities in deploying these patented products for nutraceutical use for human and animal initially. With Botanical drug interest being migrated to LiveStock Impact, Inc, the wholly owned subsidiary, Dr Liu has also migrated its directorship from BioAdaptives to LiveStock Impact, Inc.

Table of Contents

While BioAdaptives continue to investigate and acquire nutraceutical products for humans , all of our current activities are reliant on marketing and distributing products developed and owned by others. We do not own the formulations for our key products and manufacture and market them under an agreement with the developer that requires payment of a royalty and a license agreement. We are negotiating towards the acquisition of some of these formulations. Livestock Impact, Inc however, owns the exclusive marketing rights of the two equine formulations and one canine formulations.

We are reliant on direct web sales of the nutraceutical lines for human products and none of which have produced any significant revenue yet. Whereas LiveStock Impact, Inc appointed an exclusive distributor and has increased its sales volume by 400%. Because of this, we are now exploring the wholesale and white label markets for the human supplement sales. We have very limited experience in marketing and have yet to develop reliable sales expectations and forecasting.

Market and Marketing

We market our science-based, quality nutraceuticals to a broad base of the population in the U.S., and are exploring marketing prospects in Asia, Australasia, the Middle East, and Europe. The Company’s current target markets through LiveStock Impact, Inc also include equine and canine companion animals and equine competitors in the U.S., Australasia and the Middle East.

During June 2021, we commenced use of social media professionals and existing connections to create awareness about our human products’ benefits. The initial results were not satisfactory and a recast, animal product-specific program that followed later in 2021, did not achieve the desired results. We are developing affiliate marketing opportunities and recognize that a broader campaign using traditional advertising along with social media and more contemporary marketing tools is necessary. We started to re-launch our internet-based marketing activities in Q1 2023, extending the individual product websites, revamping the Company’s website, continuing to explore wholesale, white-label opportunities and placing products on Amazon. To expand its footprint on the Amazon sales channel, we are discussing with Amazon marketing specialist in third party management of our products on Amazon.

We are pursuing scientific surveys and other testing to demonstrate the usefulness of our products. While we do not anticipate developing testing protocols suitable for FDA approvals, we expect anecdotal and testimonial reports that will be useful in our marketing efforts. The Company participated in a survey involving the use of PluriPain® by patients suffering from Gadolinium Deposition Disease (“GDD”), and a combination of products for COVID Long Hauler patients. In the GDD survey, 60% of a small subject sample reported significant relief. The COVID Long Hauler survey has limited participation to date and no reported results. We continue to support these efforts.

Although we believe our last formulated MindNMemory™ and Cell Rejuven™ products are substantial improvement over PrimiLive®, our other products have not substantially changed: We offer premium nutraceutical preparations containing the best quality all-natural botanical, algal and mushroom ingredients. We will continue to emphasize the unique qualities, use and function of our nutraceuticals. We intend to create market share in our target demographic by (i) emphasizing the benefits of our proprietary algal-mushroom based, all-natural, stimulant-free, sugar-free, non-GMO ingredients that combine with proven Traditional Chinese Medicine and Ayurvedic botanicals into science-based formulations, (ii) investigating additional products in response to market demand and testing, and (iii) utilizing our marketing operation to act as its sales and distribution arm to seek additional channels for sales coverage.

Table of Contents

As noted above, we entered into licensing agreements for the PrimiLive® and PrimiSleep™ products during 2021 and changed the name PrimiSleep™ to SleepEZ™ to reflect on its capabilities as well as developing our reformulated MindnMemory™ during 2022. We also launched the advanced Cell product, Cell Rejuven™. While these products are all-natural botanical formulations, as our other nutraceutical products, they represent a departure from our existing product lines because they are targeted to specific markets: MindnMemory™ is a nootropic, intended to improve concentration and mental acuity; our initial marketing efforts are oriented toward Seniors and e-gamers. SleepEZ™ is intended for use as an aid to relaxation, with an emphasis on improving the quality of sleep. Cell Rejuven™ is an improved primitive cell anti-aging formulation that promotes high quality hair and nail growth, as well as improving mood ProteinNMore™ is a unique turbo charged balanced premium protein blend We believe these products can be used in a complementary manner, to maintain on-task endurance and then to unwind and recover from such activities.

We are furthering the use of a formulation of PluriPain® targeted toward the symptoms of pre-menstrual syndrome and menstrual pain. Anecdotal and testimonial reports have long noted that users obtain relief from these symptoms with use of the PluriPain® product, and we have made adjustments and additions to the formulation to target these symptoms. Early reports are promising, and we expect marketing efforts to emphasize the usefulness of our product to alleviate PMS-related symptoms. By popular requests, the Company is also working with developers on a menopause supplement and other targeted lifestyle supplement aids.

We are also exploring the combination of PluriPain®, PrimiLung™ and SleepEZ™ for those still suffering COVID effects in the on-going Survey conducted by Regina Sutton, M.D. These specific formulations address some of the most troubling symptoms of long-term COVID sufferers, including brain fog, pain and sleep problems.

In light of the availability of marketing funding with the first Reg A completion, we are collaborating with others to promote our products, and to also conduct surveys with larger groups of participants to further confirm their efficacy, which anecdotal reports have in the past confirmed. We look forward to the new Reg A recently filed to be qualified to further the marketing effort in reaching seniors and specific communities.

With regard to animal products, the Company’s Livestock Impact wholly owned subsidiary under the guidance of its directors, Bruce Colclasure, a National Cutting Horse Association champion, who owns and operates the Flying C Bar Ranch in Oklahoma and a breeder and trainer of over 80 NCHA champion cutting horses, as well as Dr. Charles Timmerman, D.V.M. who established a veterinary clinic since 1973 in Aikens, SC, and help test new methods for the management of various animal health problems ,continues to explore new opportunities in this emerging market. Mr. Colclasure uses and endorses our Equine All-in-One™ and derivative booster products providing valuable feedback and testimonials regarding their benefits. Dr. Timmermann has been a central contributor of scientific and clinical guidance aimed at developing breakthrough animal health products. He has helped design and execute numerous animal tests and has provided critical oversight to identify product efficacy and ensure product safety. In addition, a high-performance special formulation of our All-in-One product continues is to be marketed with exceptional results. We expect to expand the outreach in 2024.

In light of the failures of our past social media campaigns, we recommenced a social media effort this quarter with better response. The Company continues its marketing affiliate outreach program for the human products, and will continue to directly contact the principals senior communities, clubs and associations, offering discounts, samples and other inducements, seeking to develop “product champion” and “maven” relationships. We expect to contact principals in organizations with thousands of members and also through targeted advertising campaigns. With LiveStock Impact Inc, since the 4th Quarter 2022, we have been distributing samples and marketing materials to over 40 principals and influencers in regional and breed-specific equine associations and we are currently working with our exclusive distributor in a multi media advertising program for 2024.

Manufacturing

All of the Company’s nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives and LiveStock Impact products. Our active ingredients are all plant-, algal and mushroom-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices .

Table of Contents

We contract with manufacturers to assemble and package our products, all of which are subject to our inspection and approval. Fulfillment of retail internet and direct-to-reseller orders are conducted from our own facilities. BioAdaptives actively investigates new products, techniques and novel applications of existing products or technology in our research. The Company’s research work has centered on investigations of all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation.

As noted above, it is our intention to operate primarily as a research and marketing company, developing consumer markets for nutraceutical products and medical devices that we license or market for others.

Employees

The Company currently has 3 executive employees and 3 part-time employees. We retain hourly labor on an as-needed basis and professional consultants to operate our business. The management of the Company expects to continue to use outside consultants, attorneys, and accountants, as necessary, as long as it is seeking and evaluating business opportunities. The need for additional employees, and their availability, will be addressed in connection with the decision whether or not to acquire or participate in specific business opportunities.

2. LIQUITITY AND CAPITAL RESOURCES:

Liquidity -- Financial Performance – Three Months Ended September 30, 2023, and 2022

We had a net loss of $13,061 for the three-month period ended September 30 2023, which was $$263,264 less than the net loss of $276325 for the three-month period ended September 30, 2022. The change in our results is mainly due to the Change in other income (Expenses).

The following table summarizes key items of comparison and their related increase (decrease) for the Three-month periods ended September 30, 2023, and 2022:

	2023			2022			Changes
Revenue		15,649			3,337			12,312
Cost of Sales		10,999			1,337			(9,662	)
Operation Expenses		96,863			79,045			(17,822	)
Other income (expenses)		79,152			(199,280	)		278,280
Net Income (loss)		(13,061	)		(276,325	)		263,174

Revenue

Our revenues have been derived entirely from product sales. It reflects a mixture predominantly through wholesale of LiveStock Impact, Inc products and the retail of a small amount of BioAdaptives human supplements. Because of the wholesale element, margins for products are much tighter than previously when all sales were through retail web sales.

Cost of Sales

Our cost of sales is primarily derived from contract manufacturing expenses and shipping and handling expenses related to customer fulfillment. We also expense marketing expenses, which includes the cost of samples or products provided for promotional purposes and website content development. We have contracted for consulting services relating to website and product label redesign and another web sales outreach campaign, and we expect expenses to accrue for such services in 4^th.Q 2023, and beyond.

Table of Contents

Operation Expenses

Our general, administrative and professional fees are largely attributable to office, rent, advertising, consultants and transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company as well as stock-based compensation for officers, directors and consultants, as well as amortization of license and patent.

Other Income (Expense)

The Company recorded interest expenses of $20,625 and $ 94,106 for the Three months ended September30, 2023, and 2022.

Net Loss

As a result of our operating expenses the Company reported a net loss of $ 13,061 and $ 276.325 for the three months ended September 30, 2023, and 2022.

Capital Resources – Balance Sheet and Cash Flows

Our balance sheet as of September 30 2023, reflects current assets of $162,677 , including cash in the amount of $152,072 . We currently meet cash requirements by infusions of cash from issuance of notes to finance partners, through RegA subscriptions and advances from shareholders. Most of these notes have conversion features that require accounting for derivative liabilities. We are hopeful that our Reg. A+ offerings will help to reduce our financing costs but can provide no assurances as to whether our offering will be successful.

Working Capital (Deficiency)

	September 30, 2023,			September 30, 2022,			Change

Current Assets		162,677			25,941			136,736
Current Liabilities		1,475,150			1,625,473			150,323
Working Capital (Deficiency)		(1,145,848	)		(1,595,858	)		450,010

Cash Flows

	Nine Months Ended
	September 30
	2023			2022			Change
Cash provided by (used in) Operating Activities		(132,477	)		(199,755	)		66,278
Cash provided by (used in) Financing Activities		259.144			136,351			122,793
Net Increase (Decrease) In Cash During Period		152,072			19,532			132,540

Table of Contents

Net cash provided (used) by operating activities during the nine months ended September30, 2023, was $ 132,471 a decrease of $ 66,278 from net cash used of $199,755 in operating activities during the nine months ended September 30, 2022.

Cash Flows from Financing Activities

Net cash provided by financing activities during the three months ended September 30, 2023, was $ 259,144 , an increase of $122,793 from net cash provided in financing activities during the three months ended September 30, 2022 of $136,351.

As of September 30, 2023, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Critical Accounting Estimates -- Going Concern

We are required to provide qualitative and quantitative information necessary to understand any critical accounting estimations, including uncertainties associated with such estimates. Our critical accounting estimates, as well as the financial statements contained in this report, are all reliant on the assumption that we will continue as a going concern, which contemplates our ability to generate sufficient cash flows from operations and financing activities necessary to continue in business by employing our assets and satisfying our liabilities in the normal course of business.

On September 30, 2023, we had $152,072 of cash on-hand and an accumulated deficit of $7,994,864 , and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2022. We anticipate incurring significant losses in the future. We do not have an established source of revenue sufficient to cover our operating costs. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means. If we are unable to reverse our losses, we will have to discontinue operations.

Because our business plan relies on marketing products we license from others, our capital requirements are generally limited to general operations and administration, including the costs of continuing as a public company, and our variable costs scale up or down based on our actual sales. We believe that increasing our marketing expenses will be critical to establishing sales sufficient to cover our expenses and, if possible, generate a profit. We anticipate using our existing financing operations to do so, which will almost certainly require either the issuance of equity or increases in existing levels of debt or, most likely, both.

Management's plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating revenue through our business. However, even if we do raise sufficient capital to support our operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable us to develop business to a level where we will generate profits and positive cash flows from operations. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Table of Contents

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Our financial statements are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively applied that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Recent Accounting Pronouncements

The Company has evaluated recent pronouncements through Accounting Standards Updates ("ASU") and believes that none of them will have a material impact on the Company's financial position, results of operations or cash flows.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company,” we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report, September 30, 2023. This evaluation was carried out under supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company's reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to a material weakness in our internal control over financial reporting, which is described below

Table of Contents

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of September 30, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of September 30, 2023, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment. and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2024: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

To a certain extent, the size of our operation provides inherent checks and balances relative to internal controls: Because of our limited staff size and the integration of our executives and directors in operations, the prospect for significant internal control failures resulting in unreliable financial statements or worse is remote. Regardless, we recognize the importance of multiple layers of reporting and controls and are working toward improving our capabilities.

Changes in Internal Control over Financial Reporting

There was no change in the Company's internal control over financial reporting that occurred during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

At this time, we know of no pending legal proceedings to which we are a party, either individually or in the aggregate. We are from time-to-time, during the normal course of our business operations, subject to various litigation claims and legal disputes. There are no such claims or disputes pending at this time and we have not been notified of any possible claims or disputes.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Covid-19 Pandemic Impact and Risk

At this time, it is not possible to fully assess the impact of the COVID-19 pandemic on the Company’s operations and capital requirements. While we have noted that economic headwinds have eased generally, our business is impacted by numerous other influences. Business activities from 1Q 2020 onward were substantially curtailed: Our key executives were unable to travel, which impacted on our financing operations. Consumer demand was generally down in our target markets, even though we offer products that are generally considered to promote health. We delayed much of our marketing activity due to travel, funding and perceived demand issues.

Table of Contents

We re-launched our marketing efforts during 1Q 2022, but these have slowed to gain traction. The other factors impeding the growth of our business have significantly changed: travel restrictions have eased, and our finance partners have cash for investments or debt issuance. Consumer demand for our products, however, has not increased significantly. We believe this has more to do with poor reception to our marketing initiatives and the fact that we operate in a crowded market space, with several better-known and capitalized competitors.

The CDC reports that US children and adults should remain vigilant to new mutations of the COVID-19 virus, and that the pandemic will likely continue to impact groups that comprise our intended consumers. Should the pandemic reignite, the Company may be faced with the same headwinds we saw during 2021, which may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals, if required; (iv) delay, limit or preclude the Company from securing manufacturing sites, partnerships or marketing agreements; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to execute its business plan.

During 2Q 2022, the Company commenced sponsorship of a COVID Long Hauler Survey, providing funding for scientific uses and samples of our pain, pulmonary and sleep products to participants. While we do not (and cannot) make any manner of drug-type or treatment claims regarding disease, the Company has received anecdotal reports that certain combinations of our products provide relief from certain long-term COVID symptoms, including brain fog, persistent pain, and sleep disruptions. Although we are careful not to make any COVID-related claims in our marketing materials, we intend to pursue this survey for general scientific purposes to determine additional uses for our products

The Company’s priority and commitment is to the health and security of its team members, their families and its partners through this unprecedented pandemic.

The Company has no insight into what would happen if COVID is to affect the economy again with its possible resurgence.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We issued equity securities during this reporting period to satisfy subscriptions to our RegA filed in 2022:

1800 DIAGONAL LENDING, LLC	25,000,000	07/10/2023
1800 DIAGONAL LENDING, LLC	25,000,000	07/11/2023
1800 DIAGONAL LENDING, LLC	25,000,000	07/18/2023
1800 DIAGONAL LENDING, LLC	25,000,000	07/24/2023
1800 DIAGONAL LENDING, LLC	25,000,000	07/26/2023
1800 DIAGONAL LENDING, LLC	25,000,000	07/27/2023
1800 DIAGONAL LENDING, LLC	25,000,000	08/02/2023
1800 DIAGONAL LENDING, LLC	25,000,000	08/04/2023

Total	200,000,000

Additional notes will come due during the periods ending December 20, 2023, and March 21, 2024. We anticipate issuance of common shares upon 1800 Diagonal Lending’s demand.

Table of Contents

We have also filed a Reg A on October 11, 2023, once that has been qualified then 250,000,000 shares will be offered for subscription at a price to be determined between US$0.001 to US$ 0.003. Upon their subscriptions, such shares will be issued.

Item 3. Defaults Upon Senior Securities

The Company has no senior securities, but has outstanding instruments previously characterized as unsecured convertible debentures. These instruments are not senior to any other Company obligation. The Company arranged extension and forbearance agreements with the holders of the 12% Debentures, which were issued in 2018 and were due at various times in 2020. Our agreement called for the extension of these obligations on the same terms until December 31, 2021, in exchange for current interest payments and delivery of 280,000 shares of its common stock (total). We are currently in default on these obligations but are working on an alternative resolution.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Nothing to add.

Item 6. Exhibits

31.1		Section 302 Certification by the Principal Executive Officer
31.2		Section 302 Certification by the Principal Financial Officer
32.1		Section 906 Certification by the Principal Executive Officer
32.2		Section 906 Certification by the Principal Financial Officer

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BioAdaptives Inc.
		(Registrant)
Dated: November 13, 2023
		/s/ Dr. Edward E. Jacobs, M.D.
		Dr. Edward E. Jacobs, M.D.
		Chief Executive Officer


		/s/ Robert W. Ellis
		Robert W. Ellis
		Principal Financial Off

nullnullnullnull

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 08, 2023
Cover [Abstract]
Entity Registrant Name	BioAdaptives Inc.
Entity Central Index Key	0001575142
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		776,464,023
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54949
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	46-2592228
Entity Address Address Line 1	2620 Regatta Drive
Entity Address Address Line 2	Suite 102
Entity Address City Or Town	Las Vegas
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89128
City Area Code	702
Local Phone Number	659-8829
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 152,072	$ 25,405
Accounts receivable	3,344	0
Marketable securities	11	42
Inventory	7,250	8,877
Total Current Assets	162,677	34,324
License and patent, net	166,625	2,990
TOTAL ASSETS	329,302	37,314
Current Liabilities:
Accounts payable and accrued liabilities	433,375	409,920
Derivative liabilities	708,584	686,856
Current portion of convertible notes - net of discount of $79,829 and $7,647	325,671	381,793
Note payable - related party	7,520	10,246
Total Current Liabilities	1,475,150	1,488,815
Total Liabilities	1,475,150	1,488,815
Stockholders' Deficit:
Common stock ($.0001 par value, 1,250,000,000 shares authorized; 776,474,023 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)	77,647	25,255
Additional paid-in capital	6,771,839	6,074,763
Accumulated deficit	(7,995,844)	(7,551,679)
Total Stockholders' Deficit	(1,145,848)	(1,451,501)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	329,302	37,314
Series B Preferred Stock [Member]
Stockholders' Deficit:
Preferred Stock, value	225	0
Series A Preferred Stock [Member]
Stockholders' Deficit:
Preferred Stock, value	$ 285	$ 160

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Convertible notes payable current, discount	$ 79,829	$ 7,647
Preferred stock, shares par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,250,000,000	1,250,000,000
Common stock, shares issued	776,474,023	252,554,765
Common stock, shares outstanding	776,474,023	252,544,765
Common stock, shares issuable	10,000	10,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	2,250,000	0
Preferred stock, shares outstanding	2,250,000	0
Series A Preferred Stock [Member]
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	2,850,000	1,600,000
Preferred stock, shares outstanding	2,850,000	1,600,000

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
Revenues	$ 15,649	$ 3,337	$ 21,364	$ 13,192
Cost of revenue	10,999	1,337	13,244	7,096
Gross Profit	4,650	2,000	8,120	6,096
Operating Expenses
General and administrative	33,706	43,981	60,258	236,698
Professional fees	25,514	30,588	76,010	102,532
Amortization of license and patent	37,643	4,476	38,989	61,464
Total Operating Expenses	96,863	79,045	175,257	400,694
Other Income (Expense)
Unrealized gain (loss) on marketable securities	(11)	(31)	(31)	(158)
Interest expense	(20,625)	(94,106)	(123,941)	(199,572)
Change in fair value of derivative liabilities	261,488	(105,143)	8,644	(272,965)
Loss on settlement of debt	(161,700)	0	(161,700)	0
Total Other Income (Expense)	79,152	(199,280)	(277,028)	(472,695)
Loss before income taxes	(13,061)	(276,325)	(444,165)	(867,293)
Net Loss	$ (13,061)	$ (276,325)	$ (444,165)	$ (867,293)
Net Loss Per Common Share:
Basic and Diluted	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.01)
Weighted Average Number of Common Shares Outstanding:
Basic and Diluted	730,006,523	89,333,996	482,799,498	77,615,330

CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT - USD ($)	Total	Series A Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Series B, Preferred Stock
Balance, shares at Dec. 31, 2021		1,600,000				50,819,780
Balance, amount at Dec. 31, 2021	$ (1,093,039)	$ 160	$ 5,557,828	$ (6,656,109)	$ 0	$ 5,082
Common stock issued for conversion of debt, shares						7,540,799
Common stock issued for conversion of debt, amount	52,017	754	0	0	0	$ 51,263
Debts forgiveness - related party	10,000	10,000	0	0	0	0
Net loss for the period	(367,131)	$ (367,131)	5,836	5,619,091	(7,023,240)	$ 160
Balance, shares at Mar. 31, 2022		1,600,000				58,360,579
Balance, amount at Mar. 31, 2022	(1,398,153)	$ 0	119,705	0	0	$ 1,910
Balance, shares at Dec. 31, 2021		1,600,000				50,819,780
Balance, amount at Dec. 31, 2021	(1,093,039)	$ 160	5,557,828	(6,656,109)	0	$ 5,082
Debts forgiveness - related party	10,000
Net loss for the period	(867,293)
Warrant issued for Patent's acquisition	5,429
Balance, shares at Sep. 30, 2022		1,600,000				132,935,864
Balance, amount at Sep. 30, 2022	(1,595,858)
Balance, shares at Mar. 31, 2022		1,600,000				58,360,579
Balance, amount at Mar. 31, 2022	(1,398,153)	$ 0	119,705	0	0	$ 1,910
Common stock issued for conversion of debt, shares						19,096,904
Common stock issued for conversion of debt, amount	121,615	0				$ 5,429
Net loss for the period	(223,837)	$ (7,247,077)	5,548	169,865
Warrant issued for Patent's acquisition	5,429		160	7,746	5,744,225	$ 223,837
Balance, shares at Jun. 30, 2022		1,600,000				77,457,483
Balance, amount at Jun. 30, 2022	(1,494,946)			(276,325)	160
Common stock issued for conversion of debt, shares						55,478,381
Common stock issued for conversion of debt, amount	175,413	$ 13,294	$ (7,523,402)			$ 5,914,090
Net loss for the period	(276,325)
Balance, shares at Sep. 30, 2022		1,600,000				132,935,864
Balance, amount at Sep. 30, 2022	(1,595,858)
Balance, shares at Dec. 31, 2022		1,600,000	252,554,765
Balance, amount at Dec. 31, 2022	(1,451,501)	$ 160	$ 25,255	6,074,763	(7,551,679)	$ 0
Common stock issued for conversion of debt, shares			132,382,517
Common stock issued for conversion of debt, amount	108,036	0	$ 13,239	94,797	0	0
Net loss for the period	(287,187)	$ 0	$ 0	0	(287,187)	0
Balance, shares at Mar. 31, 2023		1,600,000	384,937,282
Balance, amount at Mar. 31, 2023	(1,630,652)	$ 160	$ 38,494	6,169,560	(7,838,866)	0
Balance, shares at Dec. 31, 2022		1,600,000	252,554,765
Balance, amount at Dec. 31, 2022	(1,451,501)	$ 160	$ 25,255	6,074,763	(7,551,679)	$ 0
Net loss for the period	(444,165)
Balance, shares at Sep. 30, 2023		2,850,000	776,474,023			2,250,000
Balance, amount at Sep. 30, 2023	(1,145,848)	$ 285	$ 77,647	6,771,839	(7,995,844)	$ 225
Balance, shares at Mar. 31, 2023		1,600,000	384,937,282
Balance, amount at Mar. 31, 2023	(1,630,652)	$ 160	$ 38,494	6,169,560	(7,838,866)	0
Common stock issued for conversion of debt, shares			191,536,741
Common stock issued for conversion of debt, amount	96,057	0	$ 19,153	76,904	0	0
Net loss for the period	(143,917)	$ 0	$ 0	0	(143,917)	0
Balance, shares at Jun. 30, 2023		1,600,000	576,474,023
Balance, amount at Jun. 30, 2023	(1,678,512)	$ 160	$ 57,647	6,246,464	(7,982,783)	0
Net loss for the period	(13,061)	$ 0	0	0	(13,061)	0
Series A preferred stock issued for license fee, shares		1,250,000
Series A preferred stock issued for license fee, amount	22,625	$ 125	0	22,500	0	$ 0
Series B preferred stock issued for settlement of debt - related party, shares						750,000
Series B preferred stock issued for settlement of debt - related party, amount	165,000	0	0	164,925	0	$ 75
Series B preferred stock issued for license fee, shares						1,500,000
Series B preferred stock issued for license fee, amount	180,000	0	$ 0	179,850	0	$ 150
Common stock issued for cash, shares			200,000,000
Common stock issued for cash, amount	178,100	$ 0	$ 20,000	158,100	0	$ 0
Balance, shares at Sep. 30, 2023		2,850,000	776,474,023			2,250,000
Balance, amount at Sep. 30, 2023	$ (1,145,848)	$ 285	$ 77,647	$ 6,771,839	$ (7,995,844)	$ 225

CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (444,165)	$ (867,293)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities	(8,644)	272,965
Amortization of license and patent	38,989	61,464
Amortization of debt discount	92,318	161,221
Loss on settlement of debt	161,700	0
Unrealized loss on investments in marketable securities	31	158
Changes in operating assets and liabilities:
Accounts receivable	(3,344)	0
Inventory	1,627	(3,250)
Prepaid expense and other current assets	0	1,000
Accounts payable and accrued liabilities	29,481	172,177
Due to related party	(470)	1,803
Net Cash Used in Operating Activities	(132,477)	(199,755)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance for common stock	178,100	1,623
Proceed from related party	51,044	1,623
Repayment to related party	(50,000)	(1,623)
Repayment of notes payable - related party	0	(25,272)
Proceeds from convertible notes	80,000	160,000
Net Cash Provided by Financing Activities	259,144	136,351
Net change in cash	126,667	(63,404)
Cash at beginning of period	25,405	82,936
Cash at end of period	152,072	19,532
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	0	0
Cash paid for interest		4,728
NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	150,000	142,000
Issuance of common stock for conversion of debt	204,093	349,045
Issuance Series A preferred stock for license fee	22,625
Issuance Series B preferred stock for license fee	180,000
Issuance Series B preferred stock for settlement of debt - related party	$ 165,000
Debts forgiveness - related party		10,000
Warrant issued for Patent's acquisition		$ 5,429

DESCRIPTION OF BUSINESS AND HISTORY

9 Months Ended

Sep. 30, 2023

DESCRIPTION OF BUSINESS AND HISTORY

1. DESCRIPTION OF BUSINESS AND HISTORY

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

SUMMARY OF SIGNIFICANT POLICIES

9 Months Ended

Sep. 30, 2023

SUMMARY OF SIGNIFICANT POLICIES

2. SUMMARY OF SIGNIFICANT POLICIES

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of Presentation

Use of estimates

Earnings (loss) per share

Financial Instruments and Fair Value Measurements

The following table summarizes fair value measurements by level as of September 30, 2023, and December 31, 2022, measured at fair value on a recurring basis:

	Total Carrying Value as of September 30,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	11	$	11	$	-	$	-

Liabilities
Derivative liabilities	$	708,584	$	-	$	-	$	708,584

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

Derivative Financial Instruments

GOING CONCERN

9 Months Ended

Sep. 30, 2023

GOING CONCERN

3. GOING CONCERN

3. GOING CONCERN

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

9 Months Ended

Sep. 30, 2023

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities aa of September 30, 2023, and December 31, 2022, consists of the following:

	September 30,		December 31,
	2023		2022
Accounts payable	$	4,792	$	6,939
Accrued salary		300,000		300,000
Accrued interest		127,564		101,966
Accrued liabilities		1,019		1,015
	$	433,375	$	409,920

CONVERTIBLE NOTES

9 Months Ended

Sep. 30, 2023

CONVERTIBLE NOTES

5. CONVERTIBLE NOTES

5. CONVERTIBLE NOTES

Convertible notes as of September 30, 2023, and December 31, 2022, consist of the following:

	September 30,			December 31,
	2023			2022
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		94,500			-
Total convertible notes payable		405,500			389,440

Less: Unamortized debt discount		(79,829	)		(7,647	)
Total convertible notes		325,671			381,793

Less: current portion of convertible notes		325,671			381,793
Long-term convertible notes	$	-		$	-

Conversion

Convertible Notes – Issued during the year ended December 31, 2018

	·	Term two years;

	·	Annual interest rates 12%;

	·	Convertible at the option of the holders at any time

	·	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes - Issued during the year ended December 31, 2021

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

During the year ended December 31, 2021, the Company converted principal of $172,050 and accrued interest of $6,200 into 17,787,355 shares of common stock.

Convertible Notes - Issued during the year ended December 31, 2022

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Convertible Notes - Issued during the year ended December 31, 2023

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at any time

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

DERIVATIVE LIABILITIES

9 Months Ended

Sep. 30, 2023

DERIVATIVE LIABILITIES

6. DERIVATIVE LIABILITIES

6. DERIVATIVE LIABILITIES

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

For the nine months ended September 30, 2023, and the year ended December 31, 2022, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Nine months ended			Year ended
	September 30,			December 31,
	2023			2022
Expected term	0.18- 1.00 years			0.06 - 0.51 years
Expected average volatility	141% - 288		%	72% - 164		%
Expected dividend yield		-			-
Risk-free interest rate	4.76% - 5.53		%	0.17% - 4.72		%

The following table summarizes the changes in the derivative liabilities during the nine months ended September 30, 2023.

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		150,000
Addition of new derivatives recognized as loss on derivatives		578,213
Settled on issuance of common stock		(119,628	)
Gain on change in fair value of the derivative		(586,857	)
Balance - September 30, 2023	$	708,584

The aggregate (gain) loss on derivatives during the nine months ended September 30, 2023, and 2022 was as follows.

	Nine months ended
	September 30,
	2023			2022
Day one loss due to derivative liabilities on convertible notes	$	578,213		$	44,933
(Gain) loss on change in fair value of the derivative liabilities		(586,857	)		228,032
	$	(8,644	)	$	272,965

STOCKHOLDERS EQUITY

9 Months Ended

Sep. 30, 2023

STOCKHOLDERS EQUITY

7. STOCKHOLDERS' EQUITY

7. STOCKHOLDERS’ EQUITY

Preferred Stock

Series A Preferred Stock

During the nine months ended September 30, 2023, the Company issued 1,250,000 shares of Series A Preferred Stock valued at $22,625 for license fee.

There are 2,850,000 and 1,600,000 shares of Series A shares issued as of the date of this filing as of September 30, 2023, and December 31, 2022, respectively.

Series B Preferred Stock

During the nine months ended September 30, 2023, the Company issued 1,500,000 shares of Series B Preferred Stock valued at $180,000 for license fee.

As of September 30, 2023, and December 31, 2022 2,250,000 and 0 shares of Series B Preferred Stock are issued and outstanding, respectively.

Common Stock

On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2023.

Fiscal year 2023

During the nine months ended September 30, 2023, the Company issued Common shares as follows;

	·	323,919,258 shares of common stock valued at $204,093 for conversion of debt.
	·	200,000,000 shares of common stock at $0.001 per share, net of offering cost of $21,900.

Warrant

The estimated fair values of the warrant are as follows:

	Year Ended
	December 31,
	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2023

RELATED PARTY TRANSACTIONS

8. RELATED PARTY TRANSACTIONS

8. RELATED PARTY TRANSACTIONS

Notes payable – related party.

Due to related party

License and patent

As of September 30, 2023, and December 31, 2022, License and patent consist of the following:

	September 30,			December 31,
	2023			2022
License	$	182,000		$	-
Patent		5,429			5,429
		187,429			5,429
Accumulated amortization		(20,804	)		(2,439	)
	$	166,625		$	2,990

For the nine months ended September 30, 2023, the Company recorded amortization expense of $38,989.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2023

SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

SUMMARY OF SIGNIFICANT POLICIES (Policies)

9 Months Ended

Sep. 30, 2023

SUMMARY OF SIGNIFICANT POLICIES

Basis of presentation

Use of estimates

Earnings (loss) per share

Financial Instruments and Fair Value Measurements

The following table summarizes fair value measurements by level as of September 30, 2023, and December 31, 2022, measured at fair value on a recurring basis:

	Total Carrying Value as of September 30,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	11	$	11	$	-	$	-

Liabilities
Derivative liabilities	$	708,584	$	-	$	-	$	708,584

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

Derivative Financial Instruments

SUMMARY OF SIGNIFICANT POLICIES (Tables)

9 Months Ended

Sep. 30, 2023

SUMMARY OF SIGNIFICANT POLICIES

Schedule of Fair Value of Measurements of Assets on Recurring Basis

	Total Carrying Value as of September 30,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	11	$	11	$	-	$	-

Liabilities
Derivative liabilities	$	708,584	$	-	$	-	$	708,584

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Schedule of Accounts Payable and Accrued Liabilities

	September 30,		December 31,
	2023		2022
Accounts payable	$	4,792	$	6,939
Accrued salary		300,000		300,000
Accrued interest		127,564		101,966
Accrued liabilities		1,019		1,015
	$	433,375	$	409,920

CONVERTIBLE NOTES (Tables)

9 Months Ended

Sep. 30, 2023

CONVERTIBLE NOTES

Schedule of Convertible Notes

	September 30,			December 31,
	2023			2022
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		94,500			-
Total convertible notes payable		405,500			389,440

Less: Unamortized debt discount		(79,829	)		(7,647	)
Total convertible notes		325,671			381,793

Less: current portion of convertible notes		325,671			381,793
Long-term convertible notes	$	-		$	-

DERIVATIVE LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

DERIVATIVE LIABILITIES

Schedule of Estimated Fair Values of Liabilities Measured on Recurring Basis

	Nine months ended			Year ended
	September 30,			December 31,
	2023			2022
Expected term	0.18- 1.00 years			0.06 - 0.51 years
Expected average volatility	141% - 288		%	72% - 164		%
Expected dividend yield		-			-
Risk-free interest rate	4.76% - 5.53		%	0.17% - 4.72		%

Summary of Changes in Derivative Liabilities

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		150,000
Addition of new derivatives recognized as loss on derivatives		578,213
Settled on issuance of common stock		(119,628	)
Gain on change in fair value of the derivative		(586,857	)
Balance - September 30, 2023	$	708,584

Schedule of (gain) loss on Derivatives

	Nine months ended
	September 30,
	2023			2022
Day one loss due to derivative liabilities on convertible notes	$	578,213		$	44,933
(Gain) loss on change in fair value of the derivative liabilities		(586,857	)		228,032
	$	(8,644	)	$	272,965

STOCKHOLDERS EQUITY (Tables)

9 Months Ended

Sep. 30, 2023

STOCKHOLDERS EQUITY

Schedule of Estimated Fair Values of Warrant Measured on Recurring Basis

	Year Ended
	December 31,
	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

RELATED PARTY TRANSACTIONS (Tables)

9 Months Ended

Sep. 30, 2023

RELATED PARTY TRANSACTIONS

Schedule of License and patent

	September 30,			December 31,
	2023			2022
License	$	182,000		$	-
Patent		5,429			5,429
		187,429			5,429
Accumulated amortization		(20,804	)		(2,439	)
	$	166,625		$	2,990

SUMMARY OF SIGNIFICANT POLICIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Equity Securities	$ 11	$ 42
Derivative liabilities	708,584	686,856
Fair Value, Inputs, Level 1 [Member]
Equity Securities	11	42
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Equity Securities	0	0
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Equity Securities	0	0
Derivative liabilities	$ 708,584	$ 686,856

GOING CONCERN (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
GOING CONCERN
Accumulated deficit	$ (7,995,844)	$ (7,551,679)

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable	$ 4,792	$ 6,939
Accrued salary	300,000	300,000
Accrued interest	127,564	101,966
Accrued liabilities	1,019	1,015
Accounts Payable And Accrued Liabilities	$ 433,375	$ 409,920

CONVERTIBLE NOTES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Total convertible notes payable	$ 405,500	$ 389,440
Less: Unamortized debt discount	(79,829)	(7,647)
Total convertible notes	325,671	381,793
Less: current portion of convertible notes	325,671	381,793
Long-term convertible notes	0	0
originated in April 2018 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	95,000	95,000
Originated in June 2018 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	166,000	166,000
Originated in October 2018 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	50,000	50,000
Issued fiscal year 2022 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	0	78,440
Issued fiscal year 2023 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	$ 94,500	$ 0

CONVERTIBLE NOTES (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
CONVERTIBLE NOTES (Details Narrative) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018
Debt discount	$ 150,000
Derivative loss	578,213
Amortization of debt discount	92,318	$ 161,221
Interest expenses	31,401	$ 37,903
Settled on issuance of common stock	64,258
Value Assigned of derivatives liabilities	728,213
Principal amount of convertible notes	78,440
Accrued interest of convertible notes	$ 6,026
Convertible shares of common stock	323,919,258
Accrued interest	$ 126,294		$ 100,919
Convertible Notes Payable [Member]
Principal amount of convertible notes	$ 94,500		$ 211,500	$ 222,500	$ 426,000
Description of conversion price	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date		Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price
Proceeds from Convertible notes	$ 80,000			$ 205,000	$ 426,000
Debt instrument converted amount					$ 22,210
Debt instrument converted amount shares issued				17,787,355	107,000
Convertible debt term	1 year		1 year	1 year	2 years
Annual interest rates	10.00%		10.00%	10.00%	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Convertible at any time		Convertible at 180 days from issuance	Convertible at 180 days from issuance	Convertible at the option of the holders at any time
Unpaid principal amount				$ 172,050
Accrued interest				$ 6,200

DERIVATIVE LIABILITIES (Details)	9 Months Ended	12 Months Ended
DERIVATIVE LIABILITIES (Details)	Sep. 30, 2023	Dec. 31, 2022
Expected dividend yield	0.00%	0.00%
Expected average volatility	235.00%
Risk-free interest rate	1.31%
Minimum [Member]
Expected term	2 months 4 days	21 days
Expected average volatility	141.00%	72.00%
Risk-free interest rate	4.76%	0.17%
Maximum [Member]
Expected term	1 year	6 months 3 days
Expected average volatility	288.00%	164.00%
Risk-free interest rate	5.53%	4.72%

DERIVATIVE LIABILITIES (Details 1) - USD ($)	9 Months Ended
DERIVATIVE LIABILITIES (Details 1) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
DERIVATIVE LIABILITIES
Beginnig Balance	$ 686,856
Addition of new derivatives recognized as debt discounts	150,000
Addition of new derivatives recognized as loss on derivatives	578,213
Settled on issuance of common stock	(119,628)
Gain on change in fair value of the derivative	(586,857)	$ 228,032
Ending Balance	$ 708,584

DERIVATIVE LIABILITIES (Details 2) - USD ($)	9 Months Ended
DERIVATIVE LIABILITIES (Details 2) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
DERIVATIVE LIABILITIES
Day one loss due to derivative liabilities on convertible notes	$ 578,213	$ 44,933
(Gain) loss on change in fair value of the derivative liabilities	(586,857)	228,032
Aggregate (gain) loss on derivatives	$ (8,644)	$ 272,965

STOCKHOLDERS EQUITY (Details)	9 Months Ended
STOCKHOLDERS EQUITY (Details)	Sep. 30, 2023
STOCKHOLDERS EQUITY
Expected term	2 years
Expected average volatility	235.00%
Expected dividend yield	0.00%
Risk-free interest rate	1.31%

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)			1 Months Ended	9 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Feb. 06, 2022	Feb. 06, 2020	Jan. 24, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 07, 2023	Dec. 31, 2022
Preferred stock, shares authorized				10,000,000		1,250,000,000	10,000,000
Shares Issued of common stock				323,919,258
Conversion of debt				$ 204,093
Common stock, shares outstanding				776,474,023			252,544,765
Common stock, shares par value				$ 0.0001			$ 0.0001
Common stock, shares authorized				1,250,000,000			1,250,000,000
Common stock, shares issuable				10,000			10,000
Fair value of shares granted				$ (8,644)	$ 272,965
Preferred stock, shares par value				$ 0.0001			$ 0.0001
Fiscal Year 2023 [Member]
Shares Issued of common stock				200,000,000
Net of offering cost				$ 21,900
Common stock, shares par value				$ 0.001
Series B Preferred Stock [Member]
Preferred stock, shares authorized			6,000,000	6,000,000			6,000,000
Loss on settlement of debt				$ 161,700
Settlement of debt				$ 3,300
Preferred stock, shares issued				2,250,000			0
Preferred stock, shares value for license fee, shaers				1,500,000
Preferred stock, shares par value			$ 0.0001
Preferred stock, shares value for license fee, amount				$ 180,000
Preferred stock, shares value for settlement of debt				$ 165,000
Preferred stock, shares issued for settlement of debt				750,000
Preferred stock, shares outstanding				2,250,000			0
Conversion common rights			at a 10:1 ratio
Series A Preferred Stock [Member]
Preferred stock, shares authorized		4,000,000	5,000,000	4,000,000			4,000,000
Preferred stock, shares issued				2,850,000			1,600,000
Preferred stock, shares value for license fee, shaers				1,250,000
Preferred stock, shares par value		$ 0.001
Preferred stock, shares value for license fee, amount				$ 22,625
Preferred stock, shares outstanding				2,850,000			1,600,000
Conversion common rights		at a 5:1 ratio
Common Stocks [Member]
Common stock, shares outstanding				776,474,023			252,544,765
Common stock, shares authorized						750,000,000
Common stock, shares granted	1,000,000
Exercise price	$ 0.006
Fair value of shares granted	$ 5,429

RELATED PARTY TRANSACTIONS (Details ) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
License and patent gross	$ 187,429	$ 5,429
Accumulated amortization	(20,804)	(2,439)
License and patent net	166,625	2,990
License [Member]
License and patent gross	182,000	0
Patents [Member]
License and patent gross	$ 5,429	$ 5,429

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	6 Months Ended	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2023	Dec. 31, 2022
Rate of interest		4.00%
Term of notes		1 year
Amortization expense		$ 38,989
Term of licenses range description		The term of licenses is a range from 1 to 3 years for the certain products
Repayment of notes payable - related party	$ 30,000	$ 3,300
Notes payable- related party noncurrent		5,144	$ 8,444
Interest amount	448	54
Notes payable - accrued interest		1,268	$ 1,047
Dr. Edward E. Jacobs [Member]
Due to related parties	$ 1,802	2,377
Advances to related party		51,044
Repayment of operating expenses		$ 50,470

SUBSEQUENT EVENT (Details Narrative)	Oct. 11, 2023
Subsequent Event [Member]
Marketing of common shares description	On October 11 2023, the Company filed a new Reg A for the marketing of 250,000,000 common shares at a price range of $0.001 to $0.003, to be determined after qualifying